

AD _____

Award Number: DAMD17-00-1-0274

TITLE: Structure-Based Design of erbB-2 Selective Small Molecule
Kinase Inhibitors

PRINCIPAL INVESTIGATOR: Shaomeng Wang, Ph.D.

CONTRACTING ORGANIZATION: University of Michigan
Ann Arbor, Michigan 48109-1274

REPORT DATE: July 2003

TYPE OF REPORT: Annual

20040203 033

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2003	3. REPORT TYPE AND DATES COVERED Annual (1 Jul 02-30 Jun 03)	
4. TITLE AND SUBTITLE Structure-Based Design of erbB-2 Selective Small Molecule Kinase Inhibitors			5. FUNDING NUMBERS DAMD17-00-1-0274	
6. AUTHOR(S) Shaomeng Wang, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Michigan Ann Arbor, Michigan 48109-1274 E-Mail: shaomeng@umich.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Original contains color plates. All DTIC reproductions will be in black and white.				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) No abstract provided.				
14. SUBJECT TERMS No subject terms provided.				15. NUMBER OF PAGES 7
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Task 1 – Optimization of the Activity of the Lead Compounds.....	4
Task 2 – Biological Confirmation of Potential Kinase Inhibitors and Molecular Mechanism Studies.....	4
Task 3 – Further Evaluation of In Vivo Antitumor Activity of B-17.....	6
Project Plan for Year 3.....	7
Conclusions.....	
References.....	
Appendices.....	

Task 1. Optimization of the activity of the lead compounds

Our studies in the first two years have led to the identification of a number of promising “lead” compounds. Among these initial lead compounds, **B-17** has excellent activity in inhibition of erbB-2 auto-phosphorylation and inhibition of cell proliferation using MDA-453 human breast cancer cells with erbB-2 overexpression. Furthermore, this compound appears to also be quite selective of breast cancer cells and model cells with EGFR overexpression but not erbB-2 overexpression (see below). Accordingly, **B-17** represents a quite promising lead compound for further modifications.

Based upon our predicted three-dimensional binding model for **B-17** in complex with erbB-2, we have designed a number of new analogues of **B-17**. To date, we have completed the synthesis of 10 new analogues, whose structures are provided in **Table 1**. We are currently evaluating their activity in inhibition of erbB-2 auto-phosphorylation and inhibition of cell proliferation using MDA-453 human breast cancer cells with erbB-2 overexpression. We expect that more potent and selective erbB-2 inhibitors may be obtained from these newly designed and synthesized analogues of **B-17**.

Table 1. Newly designed and synthesized analogues of B-17.

Compound	Structure	Compound	Structure
Y-6-14		Y-6-46-2	
Y-6-17		Y-6-23-1	
Y-6-11		Y-6-55	
Y-6-39-2		Y-6-99	

Task 2. Biological confirmation of potential kinase inhibitors and molecular mechanism studies

We have shown in our last yearly report (2002) that a lead compound (**B-17**) identified from our computational structure-based database searching appeared to demonstrate promising activity in inhibition of auto-phosphorylation in MDA-MB-453 breast cancer cells with overexpression of erbB-2 and selectivity in MDA-MB-468 breast cancer cells with overexpression of EGFR but not erbB-2.

Furthermore, we demonstrated that **B-17** potently inhibited cell growth in MDA-MB-453 breast cancer cells and has much less activity in MDA-MB-468 breast cancer cells. Our initial data suggested that **B-17** may be a promising erbB-2 selective kinase inhibitor. Toward further characterization of its activity, selectivity and molecular mechanism of action, we have carried out additional studies on this promising lead compound. Some of the results are summarized in this report.

Task 2.a. Further investigation of the activity and selectivity of B-17 in human breast cancer and model cell lines.

We have used two additional human breast cancer cell lines, T47D and 47T1LZ1, which overexpress erbB-2/Her-2, to evaluate the activity of **B-17**. **B-17** potently inhibits the cell growth in these two cell lines with IC₅₀ values of 0.7 and 0.7 μ M, respectively (**Table 2**). To further evaluate the selectivity of **B-17**, we have tested **B-17** in A431 cells, which have a high level of EGFR but a low level of erbB-2 expression and found that **B-17** has an IC₅₀ value of greater than 2.5 μ M. Similarly, in MDA-MB-231 cells, which have a low level of EGFR and erbB-2, **B-17** has an IC₅₀ value greater than 2.5 μ M. Thus, **B-17** potently inhibits cell growth in human breast cancer cells with a high level of erbB-2 and displays selectivity in breast cancer cells with a low level of erbB-2 but a high level of EGFR, or neither protein overexpression.

Table 2. Inhibitor effects of B-17 in cultures of erbB-2/HER-2/neu -overexpressing *versus* EGF receptor human cancer cell lines

Cell line	Overexpression	IC ₅₀ (μ M)	Cell line	Overexpression	IC ₅₀ (μ M)
			A431	EGFR	>2.5
MDA453	HER-2/erbB-2	0.29	MDA-MB468	EGFR	>2.5
T47D	HER-2/ erbB-2	0.7	NIH3T3/EGFR	EGFR	>2.5
47T1LZ1	HER-2/ erbB-2	0.7			
NIH3T3/erbB2	HER-2/ erbB-2	1.2	MDA-MB-231 (2LMP)	Neither	>2.5

Human cancer cell lines have many genetic differences between them in addition to their differences in levels of erbB-2 and EGFR proteins. To overcome this limitation, we also evaluated the activity and selectivity of **B-17** in NIH3T3 cells transfected with either erbB-2 or EGFR. **B-17** potently inhibits cell growth in NIH3T3 cells transfected with erbB-2 with an IC₅₀ value of 1.2 μ M and is less active in NIH3T3 cells transfected with EGFR. Taken together, our results demonstrated that **B-17** potently inhibits cell growth in human breast cancer and model cell lines with high levels of erbB-2 and has a relative selectivity in breast cancer cells and model cells with low levels of erbB-2.

Task 2.b. Investigation of the molecular mechanism of action of B-17 in vivo

We have demonstrated that B-17 has potent anti-tumor activity in inhibition of tumor growth in the BT-474/M1 xenograft model of human breast cancer with overexpression of erbB-2. To gain further insight on its molecular mechanism of action *in vivo*, we have investigated the effect of B-17 on the phosphorylation of erbB-2, its down-stream MAP kinase and total erbB-2 protein in BT-474/M1 cells. The results are shown in **Figure 1**. Briefly, mice bearing BT-474/M1 tumors were treated with B-17 (30 mg/kg) or with vehicle control, and the phosphorylated erbB-2 and MAPK as well as total erbB-2 protein were probed using specific antibodies for each protein. We found that while there was no apparent change in the total amount of erbB-2 protein, the phosphorylated erbB-2 protein was significantly decreased as compared to the vehicle control tumors. Furthermore, the phosphorylated MAPK protein, a downstream target of erbB-2, was also significantly decreased as compared to the vehicle control tumors. These results were consistent with our *in vitro* results, which showed that B-17 directly binds to erbB-2 protein and inhibits its kinase activity. Our *in vivo* results further suggested that the *in vivo* anti-tumor activity of B-17 is unlikely due to down-regulation of the erbB-2 protein level in cancer cells, but instead through direct inhibition of the kinase activity of erbB-2 protein.




Figure 1. *in vivo* Effects of B-17 on Phosphorylation of erbB-2, MAP kinase and total erbB-2 in BT-474/M1 cells (24 Hours after Intraperitoneal Treatment).


Task 3. Further evaluation of in vivo antitumor activity of B-17

We have further evaluated the anti-tumor activity of B-17 *in vivo* using an additional human breast cancer cell line (MDA-316/DYT2) with erbB-2 overexpression in the xenograft model (**Figure 2**). In the MDA-316/DYT2 (human breast carcinoma cells, ER positive and subclone DYT2), we

administered the B-17 on the second day after cell inoculation. With B-17 injected at 30mg/kg twice a week for three weeks, 80% tumor growth inhibition (8-10 tumors in each group) was achieved in the treated group of mice as compared to the control group with no treatment. It is noted that none of the mice showed weight loss or any other signs of toxicity at the dose regimen used.

Taken together, our *in vivo* data with two xenograft models of human breast cancer (BT-474/M1 and MDA-361/DYT2) demonstrated that B-17 has potent anti-tumor activity *in vivo*, and inhibition of the erbB-2 kinase activity using a fairly potent and erbB-2 specific small molecule kinase inhibitor has the therapeutic potential for the treatment of cancers with erbB-2 overexpression.

Figure 2. *In vivo* inhibition of tumor growth by B-17 in MDA-361/DYT2 human breast cancer xenograft model in mice.



Project Plan for Year 3.

- We will complete the characterization of these newly designed and synthesized analogues of B-17 as shown in Table 1 to identify more potent and/or more selective erbB-2 inhibitors (**Tasks 1 and 2**).
- Using two animal models of human breast cancer cell lines, we have shown that **B-17** has a potent antitumor activity *in vivo* in inhibition of tumor growth. Our results suggest that B-17 represents a promising lead compound *in vivo*. We plan to evaluate an additional 1-2 of the most promising new erbB-2 inhibitors in animal models of human breast cancer and identify the most promising erbB-2 inhibitor(s) for advanced preclinical studies.
- We plan to complete and submit 2-3 manuscripts on this project. One manuscript on the discovery of **B-17** is nearly completed.